BCL11A and sickle cell disease: Some clinical trials with gene therapy, also combined with cell platforms, were stopped due to adverse events, as it was recently disclosed during the application of autologous hematopoietic stem cells transduced with a BCL11A mRNA-encoding lentiviral vector for the treatment of sickle cell disease (Esrick et al., 2021; Statement on NHLBI decision to pause the Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for Sickle Cell Disease | NHLBI, NIH, 2021).